Biological
RotaTeq clinical trials
- studies test it
- 22
- open now
- 0
- in phase 3
- 12
- first study started
- 2001
How studies write it
Studies that test it under each name
Studies by the year they started
22 studies that test it; most in 2009 (4)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2003 | 1 |
| 2005 | 1 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 4 |
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2018 | 2 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 2
- Phase 3
- 12
- Phase 4
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 7
Merck Sharp & Dohme LLC (12) · Sanofi Pasteur, a Sanofi Company (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · PATH (1) · National Institute of Pediatrics, Mexico (1) · Children's Hospital Medical Center, Cincinnati (1) · Dennis Clements (1) · University Hospital, Brest (1)
Often tested with
Tested in the same studies.
RIX4414 vaccine (3) · Chickenpox Vaccine (2) · Hepatitis B Vaccines (2) · Poliovirus Vaccine, Inactivated (1) · Haemophilus Influenzae B Vaccine (1) · 13-valent pneumococcal vaccine (1) · Meningococcal Vaccines (1) · Pentavac (1)
Studies
Open first, then newest update. How each study uses RotaTeq is read from its arms, and is right about nine times in ten.
Testing it · 22
- Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and InfantsCompletedPhase 2Sanofi Pasteur, a Sanofi CompanyNCT04398706Written as Rotavirus Vaccine, Live, Oral, Pentavalent
- Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)CompletedPhase 3Merck Sharp & Dohme LLCNCT04481191Written as RotaTeq (V260)
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and ToddlersCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT03691610Written as Rotavirus Vaccine, Live, Oral, Pentavalent
- Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and MexicoCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT03630705Written as Rotavirus Vaccine, Live, Pentavalent
- Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected MothersCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00880698Written as RotaTeq
- Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in MaliCompletedPhase 4PATHNCT02286895Written as pentavalent rotavirus vaccine (PRV)
- Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060)CompletedPhase 4Merck Sharp & Dohme LLCNCT01926015Written as RotaTeq™ (V260)
- Randomized, Controlled Single-blind Clinical Study to Assess Vaccine Interchangeability Between RV5 and RV1 Using Seven Combined Anti-rotavirus Prevention ProgramsCompletedPhase 3National Institute of Pediatrics, MexicoNCT02193061Written as RotaTeq
- Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot StudyCompletedPhase 4Children's Hospital Medical Center, CincinnatiNCT02542462Written as RotaTeq®,
- RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)CompletedPhase 3Merck Sharp & Dohme LLCNCT00443846Written as RotaTeq®
- An Alternate Dosing Schedule for Pentavalent Rotavirus Vaccine (RotaTeq)CompletedPhase 4Dennis ClementsNCT01960725Written as RV5 (Pentavalent Rotavirus Vaccine)
- Developing World Study for RotaTeq™ (V260-015)(COMPLETED)CompletedPhase 3Merck Sharp & Dohme LLCNCT00362648Written as RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent
- Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-029)(COMPLETED)CompletedPhase 3Merck Sharp & Dohme LLCNCT00718237Written as Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™)
- Safety,Tolerability and Immunogenicity of Vaccination With Rotateq in Healthy Infants in India (V260-021)CompletedPhase 3Merck Sharp & Dohme LLCNCT00496054Written as Rotavirus Vaccine, Live, Oral, Pentavalent
- A Study of V260 in Healthy Chinese Adults, Children and Infants (V260-028)(COMPLETED)CompletedPhase 1Merck Sharp & Dohme LLCNCT00953056Written as Rotavirus Vaccine, Live, Oral, Pentavalent
- A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN)WithdrawnPhase 3Merck Sharp & Dohme LLCNCT01003431Written as Rotavirus Vaccine, Live, Oral, Pentavalent
- Consistency Lots Vaccine Study (V260-009)CompletedPhase 3Merck Sharp & Dohme LLCNCT00092456Written as rotavirus vaccine, live, oral, pentavalent
- Rotavirus Efficacy and Safety Trial (REST)(V260-006)CompletedPhase 3Merck Sharp & Dohme LLCNCT00090233Written as Rotateq™
- A Study of the Safety and Immune Response to RotaTeq™ Vaccine in the Elderly (V260-027)TerminatedPhase 1Merck Sharp & Dohme LLCNCT00836498Written as Comparator: RotaTeq
- V260 Registration Study (V260-013)(COMPLETED)CompletedPhase 3Merck Sharp & Dohme LLCNCT00166517Written as Rotavirus Vaccine, Live, Oral, Pentavalent
See all 22 studies that test RotaTeq →
Given in every arm · 13 — RotaTeq is usual care beside what is tested
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeActive, not recruitingPhase 3Sanofi Pasteur, a Sanofi CompanyNCT06736041Written as RotaTeq
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeActive, not recruitingPhase 3SanofiNCT06824194Written as RotaTeq
- Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeActive, not recruitingPhase 3SanofiNCT06824181Written as RotaTeq
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the USCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT03537508Written as Pentavalent rotavirus vaccine
- Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)CompletedPhase 3Merck Sharp & Dohme LLCNCT03893448Written as RotaTeq™
- A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)CompletedPhase 3Merck Sharp & Dohme LLCNCT03620162Written as RotaTeq™
- Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)CompletedPhase 3MCM Vaccines B.V.NCT01341639Written as RotaTeq
- Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)CompletedPhase 3MCM Vaccines B.V.NCT01839188Written as RotaTeq®
- Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)CompletedPhase 3Merck Sharp & Dohme LLCNCT01337167Written as RotaTeq™
- A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)CompletedPhase 3Merck Sharp & Dohme LLCNCT01340937Written as RotaTeq™
- Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster VaccinationCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT01839175Written as RotaTeq
- V260 Study: Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants (V260-010)CompletedPhase 3Merck Sharp & Dohme LLCNCT00258154Written as Rotavirus Vaccine, Live, Oral, Pentavalent
- Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)CompletedPhase 3Merck Sharp & Dohme LLCNCT00130832Written as Rotavirus Vaccine, Live, Oral, Pentavalent